Ionis Pharmaceuticals (IONS) return on equity (ROE)

Return on equity · fiscal 2025
-78.0%

Ionis Pharmaceuticals (IONS) earned a return on equity of -78.0% in fiscal 2025 (the year ended December 31, 2025). That is 0.8 percentage points lower than the -77.1% of fiscal 2024. Figures as of 17 Nov 2026, 17:38 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
-78.0%
Change on fiscal 2024
−0.8 pts
Highest on record
53.2%fiscal 2009
Lowest on record
-94.7%fiscal 2023
Fiscal years on record
182008–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Ionis Pharmaceuticals return on equity (ROE), in more detail

Across the 18 fiscal years on record (2008–2025), the highest was 53.2% in fiscal 2009 and the lowest -94.7% in fiscal 2023. The fiscal 2025 figure is higher than in 6% of the 17 earlier fiscal years on record, whose median is -25.0%.

History · 18 fiscal years

Return on equity by fiscal year

Ionis Pharmaceuticals return on equity (ROE), year by year

Ionis Pharmaceuticals (IONS) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
2025-78.0% 0.8 pts down
2024-77.1% 17.6 pts up
2023-94.7% 47.6 pts down
2022-47.1% 43.4 pts down
2021-3.7% 56.1 pts up
2020-59.8% 78.7 pts down
201918.9% 7.2 pts down
201826.1% 26.0 pts up
20170.1% 60.8 pts up
2016-60.7% 16.7 pts down
2015-44.0% 28.8 pts down
2014-15.1% 0.9 pts up
2013-16.0% 19.8 pts up
2012-35.8% 13.6 pts up
2011-49.5% 24.4 pts down
2010-25.0% 78.2 pts down
200953.2% 65.5 pts up
2008-12.3%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Ionis Pharmaceuticals and comparable companies
CompanyReturn on equityFiscal year
Edgewise Therapeutics EWTX-32.1%2025
LivaNova LIVN-20.2%2025
Ionis Pharmaceuticals IONS-78.0%2025
Dianthus Therapeutics DNTH-32.9%2025
MiniMed Group MMED-9.2%2026
Adaptive Biotechnologies ADPT-27.2%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on IONS

Ionis Pharmaceuticals, figure by figure

Ionis Pharmaceuticals (IONS) overview: price, valuation and scorecardAll health care companies by market value

Ionis Pharmaceuticals return on equity (ROE): questions and answers

What is Ionis Pharmaceuticals's return on equity?

Ionis Pharmaceuticals (IONS) earned a return on equity of -78.0% in fiscal 2025 (the year ended December 31, 2025). That is 0.8 percentage points lower than the -77.1% of fiscal 2024.

Is Ionis Pharmaceuticals's return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 6% of the 17 earlier fiscal years on record, whose median is -25.0%.

What are the highest and lowest return on equity figures on record for Ionis Pharmaceuticals?

Across the 18 fiscal years on record (2008–2025), the highest was 53.2% in fiscal 2009 and the lowest -94.7% in fiscal 2023.

How is Ionis Pharmaceuticals's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Ionis Pharmaceuticals (IONS) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/IONS/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.